Companies /Healthcare

Coherus Biosciences Inc

NASDAQ: CHRS Biotechnology
$1.41
▼ $0.05 (−3.42%) today
Markets closed · 12:35pm ET
Today · % change

Fundamentals

Market Cap
$217.8M
Profit Margin
-259.4%
Revenue (TTM)
$50.9M
EPS (TTM)
$-1.19
52-Week Range
$1 – $3
Street Target
$7.75

About Coherus Oncology

Coherus BioSciences Inc is a biopharmaceutical company based in Redwood City, California, specializing in biosimilars and immuno-oncology treatments. It offers products like UDENYCA, a biosimilar to Neulasta for boosting white blood cells, and CIMERLI, equivalent to Lucentis for various eye conditions. Additionally, it provides YUSIMRY, a biosimilar to Humira for inflammatory diseases. Coherus has formed strategic partnerships with several industry leaders, emphasizing its commitment to affordable healthcare solutions since its rebranding in 2012 from BioGenerics, Inc.

CHRS Coverage